Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Places Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept/Pembrolizumab in Advanced Cancers

March 8th 2022

The FDA has placed a partial clinical hold on the phase 1 NEON-2 trial examining the combination of davoceticept and pembrolizumab in patients with advanced solid tumors or lymphoma.

FDA Grants Priority Review to Ivosidenib Plus Azacitidine for Previously Untreated IDH1-Mutated AML

March 7th 2022

The FDA has granted priority review to a supplemental new drug application seeking the approval of ivosidenib in combination with azacitidine in the treatment of patients with previously untreated IDH1-mutated acute myeloid leukemia.

KarMMa Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

March 3rd 2022

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Future Management of Chronic Myeloid Leukemia

March 2nd 2022

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

February 28th 2022

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

FDA Approval Sought for Ibrutinib in Pediatric Chronic Graft-Versus-Host Disease

February 28th 2022

A supplemental new drug application has been submitted to the FDA seeking the approval of ibrutinib for the treatment of pediatric and adolescent patients aged 1 year and older with chronic graft-vs-host disease following failure of 1 or more lines of systemic therapy.

Clinical Case 3: A 56-Year-Old Man With Multiple Myeloma

February 25th 2022

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Treatment Options for Patients Progressing on Belantamab Mafodotin in MM

February 25th 2022

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Unprecedented Advances Fuel Progress in the Treatment of AL Amyloidosis

February 25th 2022

Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.

Clinical Pearls in the Management of Marginal Zone Lymphoma

February 25th 2022

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

Novel Treatment Strategies for Relapsed/Refractory MZL

February 25th 2022

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Concluding Thoughts on the DLBCL Treatment Landscape

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Key Takeaways From Discussion

February 23rd 2022

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.

Experimental Agents for ITP

February 23rd 2022

ITP experts discuss emerging ITP treatment landscape.

Sequencing in ITP

February 23rd 2022

Drs Piatek and Bussel discuss sequencing of therapies in ITP.

Monitoring Patients With Chronic Myeloid Leukemia

February 23rd 2022

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Treatment for CML: Dose Adjustment or Discontinuations

February 23rd 2022

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.